

# Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: Methodology

Michela Tinelli<sup>1</sup>, Matilde Leonardi<sup>2</sup>, Koen Paemeleire<sup>3</sup>, Dimos Mitsikostas<sup>4</sup>, Elena Ruiz de la Torre<sup>5</sup> and Timothy J Steiner<sup>6,7</sup> on behalf of the European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Federation of Neurological Associations, and *Lifting The Burden*: the Global Campaign against Headache

<sup>1</sup> Care Policy Evaluation Centre, The London School of Economics and Political Science, London, UK

<sup>2</sup> Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

<sup>3</sup> Department of Neurology, Ghent University Hospital, Ghent, Belgium

<sup>4</sup> 1st Department of Neurology, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

<sup>5</sup> European Migraine and Headache Alliance, Brussels, Belgium

<sup>6</sup> Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway

<sup>7</sup> Division of Brain Sciences, Imperial College London, London, UK

## Corresponding author:

Dr Michela Tinelli, Care Policy Evaluation Centre, The London School of Economics and Political Science, Houghton Street, London WC2A 2AE

E-mail: [m.tinelli@lse.ac.uk](mailto:m.tinelli@lse.ac.uk); Tel: +44 (0)20 7405 7686

## ABSTRACT

**Background:** Health economic evaluations support health-care decision-making by providing information on the costs and consequences of health interventions. No universally accepted methodology exists for modelling effectiveness and cost-effectiveness of interventions designed to close treatment gaps for headache disorders in countries of Europe (or elsewhere). Our aim here, within the European Brain Council's Value-of-Treatment project, was to develop headache-type-specific analytical models to be applied to implementation of structured headache services in Europe as the health-care solution to headache.

**Methods:** We developed three headache-type-specific decision-analytical models using the WHO-CHOICE framework and adapted these for three European Region country settings (Luxembourg, Russia and Spain), diverse in geographical location, population size, income level and health-care systems and for which we had population-based data. Each model compared current (suboptimal) care vs target care (delivered in accordance with the structured headache services model). Epidemiological and economic data were drawn from studies conducted by the Global Campaign against Headache; data on efficacy of treatments were taken from published randomized controlled trials; assumptions on uptake of treatments, and those made for Healthy Life Year (HLY) calculations and target-care benefits, were agreed with experts. We made annual and 5-year cost estimates from health-care provider (main analyses) and societal (secondary analyses) perspectives (2020 figures, euros).

**Results:** The analytical models were successfully developed and applied to each country setting. Headache-related costs (including use of health-care resources and lost productivity) and health outcomes (HLYs) were mapped across populations. The same calculations were repeated for each alternative (current vs target care). Analyses of the differences in costs and health outcomes between alternatives and the incremental cost-effectiveness ratios are presented elsewhere.

**Conclusions:** This study presents the first headache-type-specific analytical models to evaluate effectiveness and cost-effectiveness of implementing structured headache services in countries in the European Region. The models are robust, and can assist policy makers in allocating health budgets between interventions to maximize the health of populations.

**Word count: 313**

## Keywords

Headache, Migraine, Tension-type-headache (TTH), Medication-overuse-headache (MOH), Structured headache services, Health economics, Cost-effectiveness, Quality improvement, Healthy-Life-Years (HLYs), Global Campaign against Headache

## List of abbreviations

ASA = acetylsalicylic acid

D= expected attack duration in hours

DWs = disability weights

EBC = European Brain Council

F = frequency

GBD = Global Burden of Disease

HLY = Healthy Life Year

HLDs = hours lived with disability

ICERs = incremental cost-effectiveness ratios

MOH = medication-overuse headache

pTIS = proportion of time in ictal state

$pF_{\text{treated}}$  = proportion treated

SHR = sustained headache relief

TTH = tension-type headache

$U_{\text{cc}}$  = uptake of each treatment in current care

$U_{\text{tc}}$  = uptake of each treatment in target care

VoT = Value of Treatment

WHO = World Health Organization

YLDs = years lived with disability

## BACKGROUND

Headache disorders, principally migraine, tension-type headache (TTH) and medication-overuse headache (MOH), are responsible for 5.4% of all disability in the world and were the cause in 2019 of an estimated 46.6 million years lived with disability (YLDs) globally [1,2]. Most (88.2%) of these were attributable to migraine [3], recognized in successive iterations of the Global Burden of Disease (GBD) study as the world's second leading cause of disability [1,4-6]. Because disability leads to lost productivity, headache disorders have substantial financial impact. Each million of the population in Europe loses an estimated 400,000 days from work or school every year to migraine alone, while the estimated cost of headache disorders in Europe, due in the main to lost productivity, is well in excess of €100 billion per year [7].

Effective treatments exist for these disorders [8] but are under-utilized, largely because, in all countries, health-care systems fail to provide them [9]. The reasons are complex and not for discussion here, but they have their roots in health policies that trenchantly deny headache disorders the priority they clearly deserve [10] in view of the ill health they cause [1-6]. The solution – structured headache services – has been proposed [9], but its adoption will depend – rightly in a universal context of competition for resources – on economic evidence of cost-effectiveness, value and return on investment.

### **EBC's Value-of-Treatment project**

In 2015, the European Brain Council (EBC) initiated its Value-of-Treatment (VoT) project, building on the success of its Cost of Brain Disorders database [11,12]. VoT set out to identify obstacles, pinch-points and dead-ends in the "patient's journey" through each of nine common mental and neurological diseases, including headache, then specify remedies and, in its ultimate purpose, assess the value of improvements made in line with these remedies [13].

In the headache case, the inefficiencies and failures of the care pathway are described in previous manuscripts [9,14]. Structured headache services as the specific remedy are based in primary care in order to provide sufficient reach, with recourse to specialist services at second and third levels for the relatively few patients needing these [9]. Implementation requires educational supports at all levels, for the general public as well as health-care providers, which are built into the model [9]. With these supports, only about one third of people with headache should need professional care at any level, and primary care should effectively manage about 90% of these [9].

As for *value*, structured headache services reaching all who may benefit will be costly to implement. The up-front investment will be substantial, but so is the expected recovery of lost health [9]. Our aim here, through decision-analytical modelling, is to generate the required evidence of value needed to influence policy.

No universally accepted methodology exists for modelling effectiveness and cost-effectiveness of service-delivery interventions designed to close headache treatment gaps. This paper reports our development of methods and their use.

We describe current care and the treatment management plan to achieve target care, the types of intervention, and the coverage and uptake estimates used in three headache-type-specific decision-analytical models. We explain how we calculate economic and health outcomes, and report the key results of applying the three analytical models to population data from three paradigmatic countries in the European Region, including healthy life years (HLYs) gained and cost differences when changing from current to target care. The full economic analyses are reported elsewhere [15].

## **METHODS**

We selected three countries of the World Health Organization (WHO) European Region: Luxembourg, Russia and Spain, diverse in geographical location, population size, level of income and health-care systems. Important in these choices was that, for each, we had population-based data to support the analyses [16-18].

We developed three separate headache-type-specific decision-analytical models from an earlier exercise using the WHO-CHOICE framework [19], and simulated outcomes for the populations of 18-65-year-olds with migraine, TTH or MOH. In each model, two alternatives were compared: current (suboptimal) care vs target care delivered in accordance with the structured headache services model (see Figures 2-4). We made annual and 5-year cost estimates from health-care provider (main analyses) and societal perspectives (secondary analyses) (2020 figures, euros). We expressed effectiveness as HLYs gained and cost-effectiveness as incremental cost-effectiveness ratios (ICERs) (cost to be invested/HLY gained). We applied WHO thresholds to establish cost-effectiveness: interventions costing <3x gross domestic product (GDP) per capita per HLY were deemed cost-effective, those costing <1x GDP per capita were highly cost-effective [20]. In comparisons of current vs target care, we made the assumptions that implemented structured services with provider-training would achieve higher coverage (the proportion of people in need of a treatment who receive it), and consumer-education would lead to better adherence (the proportion who use a treatment effectively, having received it), in each case, conservatively, by 50% of the gap between current and ideal. Economic outputs included direct costs (resources sunk into health-care provision) and indirect costs (lost work productivity [see secondary analyses]). We performed sensitivity analyses with regard to how much lost productivity might be recovered to test robustness of the model.

### **Decision-analytical models: treatment management plan, selection of interventions and medicines uptake**

We developed and applied the three headache-type-specific decision-analytical models to each country setting. For each alternative (current and target care), we adopted a core set of drug interventions, focusing on those included in Linde *et al* [19]. Among these were first-line (simple analgesics: *eg*, acetylsalicylic acid (ASA) 1,000 mg) and second-line medications (*eg*, sumatriptan 50 mg) for acute treatment of attacks, with the assumption that the latter would be used only by non-responders to the former in a stepped-care treatment paradigm [8]. We

also included preventative drugs (eg, amitriptyline 100 mg daily) to be used by those with  $\geq 3.5$  headache days/month. For target care, we added to the model the expected consequences of consumer education (posters and leaflets in pharmacies explaining how to acquire and make best use of these medications) and of health-care provider training.

The treatment plans for the three headache types are described in Tables 1-3.

We estimated uptake (%) of each treatment in current care ( $U_{cc}$ ) in each of the three settings according to coverage and adherence. We took coverage data from Global Campaign studies [17,18], including the Eurolight project [16,21], and followed Linde *et al* [19] on adherence (see Tables 1-3). For target care, we calculated predicted uptake ( $U_{tc}$ ) as  $\{[(100 - U_{cc})/2] + U_{cc}\}\%$ . All details on the data used and assumptions made to calculate uptake are in Tables 1-3. We adjusted estimates of efficacy from published clinical trials by reference to uptake, better to reflect effectiveness in the real world.

## **Economic outcomes: use of resources and lost productivity according to treatment management plan**

Use of resources and lost productivity data were taken or extrapolated from different sources (Tables 1-3) [7,8,21,22]. Unit costs for health-care resources (medicines, consultations, examinations) [19] and daily wages [23] are reported in Appendix 1. We actualised costs in euros to 2020 values using the appropriate consumer price index [24]. At population level, the relationship between lost productivity and headache-attributed disability is complex (people are variably influenced by a number of extraneous and sometimes random factors) [25]. We therefore performed sensitivity analyses with regard to this. In our baseline sensitivity scenario, all lost productivity was explained by headache-attributed disability, whereas, in an alternative scenario, measurable disability accounted for only 20% of lost productivity.

## **Health outcomes: epidemiological data, disability, and estimation of intervention effectiveness**

We ran a population model for the two alternatives (current vs target care) over one- and five-year time frames to estimate total HLYs lived by the populations in each country in each alternative. The differences between these two simulations represented the population-level health gain (HLYs gained) from the intervention relative to current care. Epidemiological data were sourced from Global Campaign surveys performed in the three countries [1] (see Table 4).

We applied separate disability weights (DWs) (health state valuations on a 0–1 scale, where 1 equals full health) to the times spent in the ictal state (within-attack) and interictal state (between attacks, but susceptible). Ictal DWs (0.441 for migraine, 0.037 for TTH and 0.217 for MOH) were available from GBD2015 [26; Table 4]. For interictal DW in each disorder, to reflect interictal disability [27], we used the lowest possible weighting of 0.01 and applied it only to those with high-frequency attacks ( $\geq 3.5$ /month). For migraine and TTH, we calculated headache-attributed disability at individual level in YLDs as the product of

proportion of time in ictal state (pTIS: itself estimated as a product of attack frequency (F) and mean duration), with and without intervention, and the DW for the disorder in question. For MOH, we assumed pTIS was equal to (days/month affected)/30. To estimate disability at population level, we multiplied the means of these values by prevalence of the respective disorder.

Epidemiological data [16,17,18], including attack frequencies and durations [19], and DWs [26] for the different models are summarised in Table 4.

We modelled treatment effect as reduction in pTIS, adopting the universal outcome measure previously developed for this purpose [28] but, since this was a population-level analysis, expressing effect in terms of HLYs gained rather than hours lived with disability (HLDs) averted. Accordingly, for acute medicines, we used the clinical endpoint of "sustained headache relief" (SHR), defined as reduction in headache intensity from moderate or severe to mild or none within 2 hours and without recurrence or further medication during 24 hours. We assumed baseline headache was always at least moderate, and that mild and no pain were not associated with disability. SHR therefore implied full recovery of the remaining hours of the attack that would have been spent with disability [19,28]. We assumed that treatment was taken at attack onset, so that hours recovered per treated attack = D-2, where D = expected attack duration in hours [19,28]. Thus:

- $pTIS_{\text{untreated}} = D * F$
- $pTIS_{\text{treated}} = [(D-2)/D * (pF_{\text{treated}} * pSHR)] + \{D * [(1 - (pF_{\text{treated}} * pSHR))]\}$
- $\text{reduction in pTIS} = pTIS_{\text{untreated}} - pTIS_{\text{treated}}$

where: F = attack frequency;  $pF_{\text{treated}}$  = proportion treated; pSHR = efficacy expressed as proportion of treated attacks with SHR.

We assessed the effect of acute management and its combination in high-frequency cases with preventative drugs (modifying F), together with the potential effects of provider training on treatment coverage (modifying  $pF_{\text{treated}}$ ) and of consumer education on adherence (modifying  $pF_{\text{treated}}$  and pSHR). Data on efficacy (from randomized controlled trials) and uptake are listed in Table 5 [30-35]. For MOH we assumed success in 85% of treated cases, with reversion to other types of headache (*ie*, 2/3 to migraine and 1/3 to TTH); the other 15% would remain unchanged, but off medications.

We estimated effect per person treated per time period T years as follows:

- $YLDs_{\text{untreated}} = T * \{(pTIS_{\text{untreated}} * \text{ictal DW}) [+ (1 - [pTIS_{\text{untreated}} * \text{interictal DW}]) \text{ in high-frequency cases}]\}$ ;
- $YLDs_{\text{treated}} = T * \{(pTIS_{\text{treated}} * \text{ictal DW}) [+ (1 - [pTIS_{\text{treated}} * \text{interictal DW}]) \text{ in high-frequency cases}]\}$ ;
- $\text{HLYs gained} = YLDs_{\text{untreated}} - YLDs_{\text{treated}}$ .

In the case of MOH, HLYs gained were offset according to the assumption that treatment success implied reversion to migraine (2/3) or TTH (1/3), with HLYs lost in accordance with these disorders treated.

HLYs gained per person under a particular treatment plan were equal to the sum of the gains from each treatment multiplied by the probability of having each treatment. HLYs gained in the population were equal to HLYs gained per person multiplied by the prevalence of the disorder. Assumptions adopted when calculating the health effects are summarised in Table 5.

## RESULTS

Here we set out results for the three countries in terms of headache-related costs (including use of health-care resources and lost productivity) and health outcomes (HLYs) attached to each alternative (current vs target care) only to demonstrate how the models worked. Analyses of the differences in costs and health outcomes between alternatives and the incremental cost-effectiveness ratios are presented elsewhere [15].

### Decision-analytical models: treatment management plan and selection of interventions

Figures 2-4 represent the separate decision analytical models developed and applied to the three country settings. The complete lists of medications, corresponding uptake estimates and assumptions made according to the different management plans (current and target alternatives) for the three headache types are set out in Tables 1-3.

### Economic outcomes

Tables 6-8 report the economic outcomes attached to different treatment plans for each headache type and each country. A breakdown of the different headache costs is reported for types of medication, types of consultation, examinations and lost productivity. The same calculations are repeated for each alternative (current vs target care) and for the differences between these. For MOH, summary numbers for health-care costs and lost productivity are provided (Table 8), whereas we refer to Tables 6 and 7 (target care scenario) for costs incurred by reversion to migraine or TTH. Two separate sets of data are provided for one-year and five-year time frames.

For example, for the estimated 18,122,512 Russians with migraine (Table 6):

- current care required 303,241,487 euros invested in health care over one year, whereas
- target care (with consumer education and health-care provider training) would require 575,883,120 euros invested in health care over one year.

### Health outcomes

Table 4 reports calculated headache-attributed disabilities at individual level. Tables 9-11 report annual HLYs potentially gained by each element of the proposed treatment plan for each headache type in each country. The same



calculations are again repeated for each alternative (current vs target care) and for the differences between these. The population-level effect on health of the intervention strategies for target care, through reduced pTIS (achieved through SHR and/or reduced attack frequency), is quite substantial.

For example, for all Russians with migraine:

- current care gained an estimated 158,406 HLYs, whereas
- target care (with consumer education and health care professional training) would secure 322,115 HLYs gained (163,709 more than current care; Table 9).

## DISCUSSION

This study presents the first headache-type-specific analytical models for comparing the effectiveness and cost-effectiveness of implemented structured headache services across European Region country settings. The models linked direct costs (resources sunk into health-care provision) and indirect costs (lost work productivity) with health outcomes (in terms of HLYs). While the literature does provide a framework to assess population-level cost-effectiveness of evidence-based migraine *treatments* in low- and middle-income countries [19], data are very scarce on costs and effects of introducing headache *services* enhancing treatment delivery through a better-defined care pathway [9]. The methodology was successful, bringing together observed data for current care and estimates for target care. The flexibility of the models allowed measurements of the benefits, in people with different headache types, of care improvements achieved through implementing structured services in different countries.

The countries included – Luxembourg, Russia and Spain – were diverse in terms of geographical location, population size, level of income and organisation of their health-care systems. For example, Luxembourg was chosen because their health-care system is perceived as one of the best in Europe [36]. It has a high standard of state-funded health care covering every citizen, each having the right to choose their doctor, specialist and hospital. In Russia, although the health service is free to all, a complex compulsory medical insurance system coupled with low wages for doctors and nurses means that demands for out-of-pocket payments remain a pervasive and discouraging problem. Lastly, Spain offers free, universal health care to anyone resident, but the system is decentralised across the country's 17 autonomous regions, so that quality of care, and access to specialist procedures or units, vary across regions.

The population and costing models rest upon a series of best estimates, including the expected patterns of resource use and intervention efficacy. Data to support these in each of the three countries were sourced from population-based studies in Russia [17,18] and the Eurolight project for Luxembourg and Spain [16]. Unfortunately, in Eurolight, participation proportions were suboptimal and samples might not be truly representative [36]. Participants were not asked about formulations of acute medicines, and the numbers of doses were estimated conservatively. For preventative medicines, it was assumed that recommended doses were used [8,19].

In addition, effectiveness data were drawn from published controlled trials, which did not always include the countries in question. All findings might also be sensitive to assumptions made in the costing model, and to possible variations in the national statistics applied (see Table 4).

Even though the indirect costs of migraine and MOH dominate the direct costs, productivity gains and lost-time costs were not taken into consideration in our main analyses because no internationally agreed approach is yet available to measure these satisfactorily [7,11]. However, in our sensitivity analyses, we used the human capital approach as the most common method for estimating the economic value of employee productivity, assuming that it is equal to gross earnings [38]. This allowed us to re-run the models from the broader societal perspective, covering both health-care provider costs and those due to lost productivity.

A major difficulty lay in the relationship between headache-attributed disability, estimated from DWs generated in GBD2015, and headache-attributed lost work productivity. A strong correlation was intuitively expected. In our baseline scenario, we assumed that lost productivity was fully explained by headache-attributed disability: *ie*, reductions in disability would bring commensurate reductions in lost productivity. This may not be so at population level because, as mentioned earlier, people are variably influenced by a number of extraneous and sometimes random factors [26]. The sensitivity analyses showed that varying the proportion of lost productivity recovered had a major impact on economic estimates. This was expected, because predicted savings in work productivity greatly exceeded the investments in health care estimated to be needed to achieve these savings. Nevertheless, in a conservative scenario, where we assumed that remedying disability would recover only 20% of the lost productivity attributed to it, the intervention remained cost-effective in all models and cost-saving in Luxembourg. Furthermore, at *individual* level (relevant in the context of treatment), the extraneous factors are mostly constant, meaning a simpler and closer relationship was likely [25].

## **CONCLUSION**

Despite these limitations, the study delivered robust models, with detailed results presented in the next paper in this series [15]. The models should greatly assist local health-policy makers, across Europe and very probably elsewhere, in allocating fixed health budgets between interventions to maximise health in society. Health-care systems vary widely even within the European Region, and certainly outside it, but the analytical models should be applicable to any that adopt and fully implement the services model [9]. Widely different costs (such as input costs and income levels) may of course lead to different analytical outcomes.

## **DECLARATIONS**

### **Ethics approval**

Not applicable. Ethics approval was not needed for these economic analyses supported by published data.

## **Consent for publication**

Not applicable.

## **Availability of data and material**

All data generated or analysed during this study are included in this published article.

## **Competing interests**

The authors declare that they have no competing interests.

## **Funding**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The work was supported by the European Brain Council as part of the Value of Treatment Project.

## **Authors' contributions**

All authors supported the conception and design of the project. MT and TS developed the economic evaluation framework and led the data analysis and interpretation. MT produced the first draft and TS was a major contributor in writing the manuscript. All authors read and commented on the manuscript drafts and approved the final version.

## **Acknowledgements**

Not applicable.

## REFERENCES


1. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396: 1204-1222.
2. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of *Lifting The Burden: the Global Campaign against Headache* (2020) Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. *J Headache Pain* 21: 137.
3. Institute for Health Metrics and Evaluation (2020) At: [http://www.healthdata.org/results/gbd\\_summaries/2019/headache-disorders-level-3-cause](http://www.healthdata.org/results/gbd_summaries/2019/headache-disorders-level-3-cause) [last accessed: 13 December 2020].
4. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, Ackerman IN, Adamu AA, Adetokunboh O, Afarideh M, Afshin A, Agarwal SK, Aggarwal R, Agrawal A, Agrawal S, Ahmadi H, Ahmed MB, Aichour MTE, Aichour AN, Aichour I, Aiyar S, Akinyemi RO, Akseer N, Al Lami FH, Alahdab F, Al-Aly Z, Alam K, Alam N, Alam T, Alasfoor D et al (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 390: 1211-1259.
5. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, Ansha MG, Barac A, Bensenor IM, Doan LP, Edessa D, Endres M, Foreman KJ, Gankpe FG, Gururaj G, Goulart AC, Gupta R, Hankey GJ, Hay SI, Hegazy MI, Hilawe EH, Kasaeian A, Kassa DH, Khalil I, Khang Y-H, Khubchandani J, Kim YJ, Kokubo Y, Mohammed MA, Moradi-Lakeh M, Nguyen HLT, Nirayo YL, Qorbani M, Ranta A, Roba KT, Safiri S, Santos IS, Satpathy M, Sawhney M, Shiferaw MS, Shiue I, Smith M, Szoeki CEI, Truong NT, Venketasubramanian N, Weldegwergs KG, Westerman R, Wijeratne T, Xuan Tran B, Yonemoto N, Feigin VL, Vos T, Murray CJL (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 17: 954-976.
6. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study. *Lancet* 392: 1789–1858.
7. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2012) The cost of headache disorders in Europe: the Eurolight project. *Eur J Neurol* 19: 703–711.
8. Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P on behalf of the European Headache Federation and *Lifting The Burden: the Global Campaign*

- against Headache (2019) Aids to management of headache disorders in primary care (2nd edition). *J Headache Pain* 20: 57.
9. Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Guðmundsson LS, Herekar AA, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, Ruiz de la Torre E, Saylor D, Togha M, Yu SY, Zebenigus M, Zenebe Zewde Y, Zidverc-Trajković J, Tinelli M on behalf of *Lifting The Burden: the Global Campaign against Headache* (2021). Structured headache services as the solution to the ill-health burden of headache. 1. Rationale and description. *J Headache Pain* (details to be added in proof).
  10. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? *J Headache Pain* 19: 17.
  11. Gustavasson A, Svensson M, Jacobi F (2011) Cost of disorders of the brain in Europe 2010. *Eur Psychopharmacology* 21:718-779.
  12. DiLuca M, Olesen J (2014). The cost of brain diseases: a burden or a challenge? *Neuron* 82: 1205–1208.
  13. European Brain Council (2017) The Value of treatment project. Policy white paper. Available at: <http://www.braincouncil.eu/activities/projects/value-of-treatment-policy-white-paper> [last accessed: 13 December 2020].
  14. Leonardi M, Ruiz De La Torre E, Steiner T, Tinelli, M Raggi A, D'Amico D, Grazi L, Paemeleire K, Mitsikostas D (2018) Value of treatment of headache patients and need to improve headache patients' journey. *Neurol Sci* 39: 115-116.
  15. Tinelli M, Leonardi M, Paemeleire K, Raggi A, Mitsikostas D, de la Torre ER, Steiner TJ on behalf of the European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Federation of Neurological Associations, and *Lifting The Burden: the Global Campaign against Headache* (2021) Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: Results. *J Headache Pain* (details to be added in proof).
  16. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C (2014) The impact of headache in Europe: principal results of the Eurolight project. *J Headache Pain* 15: 31.
  17. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ (2012) The prevalence of primary headache disorders in Russia: a countrywide survey. *Cephalalgia* 32: 373-381.
  18. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Steiner TJ (2014) Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. *Eur J Neurol* 21: 758-765.

19. Linde M, Steiner TJ, Chisholm D (2015) Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries *J Headache Pain* 16: 15.
20. World Health Organization. WHO-CHOICE (CHOosing Interventions that are Cost-Effective) project. WHO: Geneva, 2014. Available at: <https://www.who.int/choice/cost-effectiveness/en/> [last accessed: 13 December 2020].
21. Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. *J Headache Pain* 19: 10.
22. Yu J, Goodman MJ, Oderda GM. Economic evaluation of pharmacotherapy of migraine pain: a review of the literature (2009) *J Pain Palliat Care Pharmacother* 23: 396–408.
23. <http://www.wageindicator.org/main/salary/Salarycheckers> [last accessed: 13 December 2020].
24. European Central Bank. Statistical Data Warehouse. Eurosystem. <http://sdw.ecb.europa.eu/> [last accessed: 5 October 2020].
25. planned JHP paper reporting on the relationship between lost work productivity and disease-related disability. Now Paper 4
26. WHO. WHO methods and data sources for global burden of disease estimates 2000-2015. (2017) Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2017.1 [https://www.who.int/healthinfo/global\\_burden\\_disease/GlobalDALYmethods\\_2000\\_2015.pdf](https://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf) [last accessed: 5 October 2020].
27. Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, Laínez JMA, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Andrée C, Steiner TJ. Interictal burden attributable to episodic headache: findings from the Eurolight project (2016) *J Headache Pain* 17: 9.
28. Steiner TJ, Linde M, Schnell-Inderst P (2021) A universal outcome measure for headache treatments, care-delivery systems and economic analysis. *J Headache Pain* (details to be added in proof).
29. <http://www.worldometers.info> [last accessed: 13 December 2020].
30. <http://data.worldbank.org> [last accessed: 13 December 2020].
31. Kirthi V, Derry S, Moore RA (2010) Aspirin with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev* 4: CD008041.
32. Derry CJ, Derry S, Moore RA (2012) Sumatriptan (oral route of administration) for acute migraine attacks in adults. *Cochrane Database Syst Rev* 2(2): CD008615.
33. Dodick DW, Freitag F, Banks J (2009) Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther* 31: 542–559.

34. Stephens G, Derry S, Moore RA (2016) Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults Cochrane Database Syst Rev 6: CD011889.
35. World Health Organization. Luxembourg: Country Health Profile 2017. In series: State of Health in the EU (2017). Available at: [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0011/355988/Health-Profile-Luxembourg-Eng.pdf?ua=1](http://www.euro.who.int/__data/assets/pdf_file/0011/355988/Health-Profile-Luxembourg-Eng.pdf?ua=1) [last accessed: 13 December 2020].
36. Andrée C, Stovner LJ, Steiner TJ, Barre J, Katsarava Z, Lainez JM, Lair M-L, Lanteri-Minet M, Mick G, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Vriezen P, Lampl C (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. *J Headache Pain* 12: 541-549.
37. Torrance GW, Stoddart GL, Drummond MF (2005) *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University press (third edition).
38. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. *Cephalalgia* 27:193-210.
39. *Lifting The Burden*. At <http://www.l-t-b.org> [last accessed: 13 December 2020].
40. World Health Organization, *Lifting The Burden*. Atlas of headache disorders and resources in the world 2011. WHO Geneva. Available at: [http://www.who.int/mental\\_health/management/who\\_atlas\\_headache\\_disorders.pdf?ua=1](http://www.who.int/mental_health/management/who_atlas_headache_disorders.pdf?ua=1) [last accessed: 13 December 2020].

**Figure 1: Template for structured headache services supported by educational initiatives, and expected patient flows** (as described in [9]: structured headache services are based in primary care and supported by specialist care; educational initiatives are aimed at health-care providers to improve competence at their level, and at the public to promote self-care and effective use of both over-the-counter (OTC) drugs and headache services; pharmacists advise on use of OTC and other drugs, discouraging overuse, and on use of headache services; within these services, everyone with headache should make best use of OTC drugs; about one third of people with headache need professional health care; primary care provides effective management for most of these, while specialist care is reserved for the small proportion who need it)






**Figure 2: Analytical models for Luxembourg** (data are reported in Table 1)

**MIGRAINE current care** (estimates derived from published data, see treatment plan, Table 1)




**MIGRAINE target care** (expert assumptions)




**TTH current care** (estimates derived from published data, see treatment plan, Table 1)




**TTH target care** (expert assumptions)



**MOH current care** (estimates derived from published data, see treatment plan, Table 1)




**MOH target care** (expert assumptions)




**Figure 3: Analytical models for Russia** (data are reported in Table 2)

**MIGRAINE current care** (estimates derived from published data, see treatment plan, Table 1)




**MIGRAINE target care** (expert assumptions)




**TTH current care** (estimates derived from published data, see treatment plan, Table 1)




**TTH target care** (expert assumptions)



**MOH current care** (estimates derived from published data, see treatment plan, Table 1)




**MOH target care** (expert assumptions)




**Figure 4: Analytical models for Spain** (data are reported in Table 3)

**MIGRAINE current care** (estimates derived from published data, see treatment plan, Table 1)




**MIGRAINE Target care** (expert assumptions)




**TTH current care** (estimates derived from published data, see treatment plan, Table 1)




**TTH Target care** (expert assumptions)



**MOH current care** (estimates derived from published data, see treatment plan, Table 1)



**MOH Target care** (expert assumptions)



**Table 1: Treatment uptake, use of resources and lost productivity according to treatment management plan (Luxembourg)**

	<b>Headache type</b>	<b>Current care (%)</b>	<b>Target care (%)</b>	<b>Notes</b>
<b>Uptake (including coverage and adherence)</b>	<b>Migraine</b>	83.8	91.9	<b>Current care:</b> 72.1% migraine non-specific; 7.1% migraine specific; 4.6% migraine prophylaxis (see treatment plan below) <b>Target care:</b> We assumed that structured services with consumer education and provider training enhances coverage and adherence so that uptake is increased by 50% of current deficit: medicines uptake = $[\{100\% - 83.8\% \} / 2] + 83.8\%$ = 91.9%
	<b>TTH</b>	58.2	79.1	<b>Current care:</b> 58.2% acute medications; 0% TTH prophylaxis (see treatment plan below) <b>Target care:</b> We assumed as above: medicines uptake = $[\{100\% - 58.2\% \} / 2] + 58.2\%$ = 79.1%
	<b>MOH</b>	0	50.0	<b>Current care:</b> 0% treated <b>Target care:</b> We assumed that structured services with consumer education and provider training enhances treatment coverage and adherence so that proportion withdrawn from medicines overuse is increased by 50% of current deficit: withdrawal = $[\{100 - 0\% \} / 2] + 0\%$ = 50.0%
<b>TREATMENT PLAN</b>				
<b>A. Acute management (non-specific drugs)</b>				
<b>Simple analgesics (eg, ASA 1 g)</b>	<b>Migraine</b>	72.1	46.0	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With consumer education and provider training, treatment with simple analgesics alone is used by or offered to 50% (expert assumption), with uptake = 46.0% (50% of 91.9%)
	<b>TTH</b>	55.6	76.7	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With consumer education and provider training, treatment with simple analgesics alone is used by or offered to 97% (expert assumption), with uptake 76.7% (97% of 79.1%)
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>B. Acute management (specific drugs)</b>				
	<b>Migraine</b>	7.1	0	<b>Current care:</b> from Eurolight data [21]

<b>Sumatriptan 50 mg</b>				<b>Target care:</b> With provider training, treatment with specific drugs alone is offered to 0% (expert assumption)
	<b>TTH</b>	0	0	Not applicable to TTH care
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>C. Acute stepped-care management</b>				
<b>ASA 1 g + sumatriptan 50 mg</b>	<b>Migraine</b>	0	18.4	<b>Current care:</b> not included in current care <b>Target care:</b> With provider training, acute stepped-care management is offered to 20% (expert assumption), with uptake = 18.4% (20% of 91.9%)
	<b>TTH</b>	0	0	Not applicable to TTH care
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>D. Prophylaxis + acute management</b>				
<b>Amitriptyline 100 mg/day + ASA 1 g + sumatriptan 50 mg</b>	<b>Migraine</b>	4.6	27.6	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With provider training, prophylaxis + acute stepped-care management is offered to 30% (expert assumption), with uptake = 27.6% (30% of 91.9%)
	<b>TTH</b>	0	2.4	<b>Current care:</b> not included in current care <b>Target care:</b> With provider training, prophylaxis + acute care management is offered to 3% (expert assumption), with uptake = 2.4% (3% of 79.1%)
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>Consultations and investigations</b>				
<b>Doctor visits (year 1)</b>	<b>Migraine</b>	25.1	50.0	<b>Current care:</b> 25.1% with migraine had seen a doctor (Eurolight data [21]), of whom 19.3% had seen a GP and 5.8% a specialist. We assumed 2 visits in either case. <b>Target care:</b> With consumer education, 50% see a doctor (expert assumption based on estimated need for professional care). Note that in the model those who see a specialist would see a GP first.
	<b>TTH</b>	9.4	2.25	<b>Current care:</b> 9.4% with TTH had seen a doctor (Eurolight data [21]), of whom 6.9% had seen a GP and 2.5% a specialist. We assumed 2 visits in either case.

				<p><b>Target care:</b> With consumer education, 3% (Stovner 2007 [38]) x 75% = 2.25% see a specialist and none see a GP (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2% with MOH had seen a doctor (Eurolight data [21]), of whom 21.6% had seen a GP and 29.6% a specialist. We assumed 2 visits in either case.</p> <p><b>Target care:</b> With consumer education, 100% see a doctor (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
<b>GP visits</b>	<b>Migraine</b>	19.3	45.0	<p><b>Current care:</b> 19.3% had seen a GP (Eurolight data [21])</p> <p><b>Target care:</b> With consumer education, 45.0% (90% of 50%) see a GP (we assumed 2 visits in a year)</p>
	<b>TTH</b>	6.9	0	<p><b>Current care:</b> 6.9% had seen a GP (2 times in a year) (Eurolight data [21])</p> <p><b>Target care:</b> Chronic TTH is difficult to treat, so we assumed that all should go to levels 2 or 3 (ie, "specialists").</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	21.6	100	<p><b>Current care:</b> 21.6% had seen a GP (2 times in a year) (Eurolight data [21])</p> <p><b>Target care:</b> With consumer education, 100% see a GP (we assumed 2 visits in a year)</p>
<b>Specialist visits</b>	<b>Migraine</b>	5.8	5.0	<p><b>Current care:</b> 5.8% had seen a specialist (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 5.0% (10% of 50%) see a specialist (we assumed 2 visits in a year)</p>
	<b>TTH</b>	2.5	2.25	<p><b>Current care:</b> 2.5% had seen a specialist (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 2.25% see a specialist (we assumed 2 visits in a year)</p>
	<b>MOH</b>	29.6	100	<p><b>Current care:</b> 29.6 % saw a GP (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 100% see a specialist (we assumed 2 visits in a year)</p>
<b>Investigations (MRI) (year 1)</b>	<b>Migraine</b>	8.5	1.0	<p><b>Current care:</b> All those seeing a specialist had MRI (one in a year)</p> <p><b>Target care:</b> With provider training, we assumed 1% have MRI (one in a year)</p>

	<b>TTH</b>	1.0	0.5	<p><b>Current care:</b> 1% had an MRI</p> <p><b>Target care:</b> We assumed 0.5% have MRI examination (one in a year) – half the current estimate</p>
	<b>MOH</b>	0	0	<p><b>Current care:</b> Nobody had an MRI</p> <p><b>Target care:</b> Nobody has an MRI</p>
<b>Doctor visits (years 2-5)</b>	<b>Migraine</b>	24.6	50.0	<p><b>Current care:</b> 24.6% with migraine had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 50% see a doctor (expert assumption based on estimated need for professional care)</p>
	<b>TTH</b>	9.4	2.25	<p><b>Current care:</b> 9.4% with TTH had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 3% (Stovner 2007 [38]) x 75% = 2.25% see a doctor (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2% with MOH had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 100% see a doctor</p>
<b>GP visits</b>	<b>Migraine</b>	24.6	50.0	<p><b>Current care:</b> 24.6% saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> With consumer education, 50% see a GP. We assumed 2 visits each year.</p>
	<b>TTH</b>	9.4	0	<p><b>Current care:</b> 9.4% saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> Chronic TTH is difficult to treat, so we assumed that all should go to levels 2 or 3 (ie, "specialists").</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2 % saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> With consumer education, 100% see a GP. We assumed 2 visits each year.</p>
<b>Specialist visits</b>	<b>Migraine</b>	0	0	<p><b>Current care:</b> No visits after year 1</p> <p><b>Target care:</b> No visits after year 1</p>
	<b>TTH</b>	0	2.25	<p><b>Current care:</b> No visits after year 1</p>

				<b>Target care:</b> With consumer education and provider training, 2.25% see a specialist (we assumed 2 visits in a year).
	<b>MOH</b>	0	0	<b>Current care:</b> No visits after year 1 <b>Target care:</b> No visits after year 1
<b>Investigation (MRI) (years 2-5)</b>	<b>Migraine</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
	<b>TTH</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
	<b>MOH</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
<b>Lost productivity</b>	We assumed that lost work productivity was correlated with disease-attributed disability, and reduced disability would bring reduced lost productivity. In our baseline scenario, all lost productivity was explained by disease-attributed disability.			
<b>Days lost from work in 12 months</b>	<b>Migraine</b>	7.6	2.4	<b>Current care:</b> Based on Eurolight data [16] <b>Target care:</b> We assumed 69% decrease in lost productivity (equal to the gain in HLYs reported for migraine [see Table 4]): $7.6 - (7.6 * 0.69) = 2.4$ days.
	<b>TTH</b>	3.2	1.0	<b>Current care:</b> Based on Eurolight data [16] <b>Target care:</b> We assumed 76% decrease in lost productivity (equal to the gain in HLYs reported for TTH [see Table 4]): $3.2 - (3.2 * 0.76) = 1.0$ days.
	<b>MOH</b>	22.8	7.1 (if revert to migraine); 5.5 (if revert to TTH)	<b>Current care:</b> Based on Eurolight data [16] <b>Target care:</b> For individuals reverting to migraine, we assumed 69% decrease in lost productivity (equal to the gain in HLYs reported for migraine [see Table 4]): $22.8 - (22.8 * 0.69) = 7.1$ days For individuals reverting to TTH, we assumed 76% decrease in lost productivity (equal to the gain in HLYs reported for TTH [see Table 4]): $22.8 - (22.8 * 0.76) = 5.5$ days.



**Table 2: Treatment uptake, use of resources and lost productivity according to treatment management plan (Russia)**

	<b>Headache type</b>	<b>Current care (%)</b>	<b>Target care (%)</b>	<b>Notes</b>
<b>Uptake (including coverage and adherence)</b>	<b>Migraine</b>	64.7	82.0	<p><b>Current care:</b> 63.5% migraine non-specific; 0.5% migraine specific; 0.7% migraine prophylaxis</p> <p><b>Target care:</b> We assumed that structured services with consumer education and provider training enhances coverage and adherence so that overall uptake is increased by 50%; medicines uptake = <math>[\{100\% - 64.7\% \} / 2] + 64.7\%</math> = 82.0%</p>
	<b>TTH</b>	55.6	77.8	<p>55.6% (acute medications) TTH; 0% TTH prophylaxis (see treatment plan below)</p> <p><b>Target care:</b> We assumed as above; medicines uptake = <math>[\{100\% - 55.6\% \} / 2] + 55.6\%</math> = 77.8%</p>
	<b>MOH</b>	0	50.0	<p><b>Current care:</b> 0% treated</p> <p><b>Target care:</b> We assumed that structured services with consumer education and provider training enhances treatment coverage and adherence so that proportion withdrawn from medicines overuse is increased by 50% of current deficit: withdrawal = <math>[\{100 - 0\% \} / 2] + 0\%</math> = 50%</p>
<b>TREATMENT PLAN</b>				
<b>A. Acute management (non-specific drugs)</b>				
<b>Simple analgesics (eg, ASA 1 g)</b>	<b>Migraine</b>	63.5	41.0	<p><b>Current care:</b> from Eurolight data [21]</p> <p><b>Target care:</b> With provider training, treatment with simple analgesics alone is offered to 50% (expert assumption), with uptake = 41.0% (50% of 82.0%)</p>
	<b>TTH</b>	55.6	75.5	<p><b>Current care:</b> from Eurolight data [21]</p> <p><b>Target care:</b> With provider training, treatment with simple analgesics alone is offered to 97% (expert assumption), with uptake = 75.5% (97% of 77.8%)</p>
	<b>MOH</b>	0	0	Not applicable to MOH care

<b>B. Acute management (specific drugs)</b>				
<b>Sumatriptan 50 mg</b>	<b>Migraine</b>	0.5	0	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With provider training, treatment with specific drugs alone is offered to 0% (expert assumption)
	<b>TTH</b>	0	0	Not applicable to TTH care
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>C. Acute stepped-care management</b>				
<b>ASA 1 g + sumatriptan 50 mg</b>	<b>Migraine</b>	0	16.4	<b>Current care:</b> not included in current care <b>Target care:</b> With provider training, acute stepped-care management is offered to 20% (expert assumption), with uptake = 16.4% (20% of 82.0%)
	<b>TTH</b>	0	0	Not applicable to TTH care
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>D. Prophylaxis + acute management</b>				
<b>Amitriptyline 100 mg/day + ASA 1 g + sumatriptan 50 mg</b>	<b>Migraine</b>	0.7	24.6	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With provider training, prophylaxis + acute stepped-care management is offered to 30% (expert assumption), with uptake = 24.6% (30% of 82.0%)
	<b>TTH</b>	0	2.3	<b>Current care:</b> not included in current care <b>Target care:</b> With provider training, prophylaxis + acute care management is offered to 3% (expert assumption), with uptake = 2.3% (3% of 77.8%)
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>Consultations and investigations</b>				
<b>Doctor visits (year 1)</b>	<b>Migraine</b>	25.1	50.0	<b>Current care:</b> 25.1% with migraine had seen a doctor (Eurolight data [21]), of whom 19.3% had seen a GP and 5.8% a specialist. We assumed 2 visits in either case. <b>Target care:</b> With consumer education, 50% see a doctor (expert assumption based on estimated need for professional care). Note that in the model those who see a specialist would see a GP first.
	<b>TTH</b>	9.4	2.25	<b>Current care:</b> 9.4% with TTH had seen a doctor (Eurolight data [21]), of whom 6.9% had seen a GP and 2.5% a specialist. We assumed 2 visits in either case.

				<p><b>Target care:</b> With consumer education, 3% (Stovner 2007 [38]) x 75% = 2.25% see a specialist and none see a GP (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2% with MOH had seen a doctor (Eurolight data [21]), of whom 21.6% had seen a GP and 29.6% a specialist. We assumed 2 visits in either case.</p> <p><b>Target care:</b> With consumer education, 100% see a doctor (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
<b>GP visits</b>	<b>Migraine</b>	19.3	45.0	<p><b>Current care:</b> 19.3% had seen a GP (Eurolight data [21])</p> <p><b>Target care:</b> With consumer education, 45.0% (90% of 50%) see a GP (we assumed 2 visits in a year)</p>
	<b>TTH</b>	6.9	0	<p><b>Current care:</b> 6.9% had seen a GP (2 times in a year) (Eurolight data [21])</p> <p><b>Target care:</b> Chronic TTH is difficult to treat, so we assumed that all should go to levels 2 or 3 (ie, "specialists").</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	21.6	100	<p><b>Current care:</b> 21.6% had seen a GP (2 times in a year) (Eurolight data [21])</p> <p><b>Target care:</b> With consumer education, 100% see a GP (we assumed 2 visits in a year)</p>
<b>Specialist visits</b>	<b>Migraine</b>	5.8	5.0	<p><b>Current care:</b> 5.8% had seen a specialist (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 5.0% (10% of 50%) see a specialist (we assumed 2 visits in a year)</p>
	<b>TTH</b>	2.5	2.25	<p><b>Current care:</b> 2.5% had seen a specialist (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 2.25% see a specialist (we assumed 2 visits in a year)</p>
	<b>MOH</b>	29.6	100	<p><b>Current care:</b> 29.6 % saw a GP (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 100% see a specialist (we assumed 2 visits in a year)</p>
<b>Investigations (MRI) (year one)</b>	<b>Migraine</b>	8.5	1.0	<p><b>Current care:</b> All those seeing a specialist had MRI (one in a year)</p> <p><b>Target care:</b> With provider training, we assumed 1% have MRI (one in a year)</p>

	<b>TTH</b>	1.0	0.5	<p><b>Current care:</b> 1% had an MRI</p> <p><b>Target care:</b> We assumed 0.5% have MRI examination (one in a year) – half the current estimate</p>
	<b>MOH</b>	0	0	<p><b>Current care:</b> Nobody had an MRI</p> <p><b>Target care:</b> Nobody has an MRI</p>
<b>Doctor visits (years 2-5)</b>	<b>Migraine</b>	24.6	50.0	<p><b>Current care:</b> 24.6% with migraine had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 50% see a doctor (expert assumption based on estimated need for professional care)</p>
	<b>TTH</b>	9.4	2.25	<p><b>Current care:</b> 9.4% with TTH had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 3% (Stovner 2007 [38]) x 75% = 2.25% see a doctor (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2% with MOH had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 100% see a doctor</p>
<b>GP visits</b>	<b>Migraine</b>	24.6	50.0	<p><b>Current care:</b> 24.6% saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> With consumer education, 50% see a GP. We assumed 2 visits each year.</p>
	<b>TTH</b>	9.4	0	<p><b>Current care:</b> 9.4% saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> Chronic TTH is difficult to treat, so we assumed that all should go to levels 2 or 3 (ie, "specialists").</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2 % saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> With consumer education, 100% see a GP. We assumed 2 visits each year.</p>
<b>Specialist visits</b>	<b>Migraine</b>	0	0	<p><b>Current care:</b> No visits after year 1</p> <p><b>Target care:</b> No visits after year 1</p>
	<b>TTH</b>	0	2.25	<p><b>Current care:</b> No visits after year 1</p>

				<b>Target care:</b> With consumer education and provider training, 2.25% see a specialist (we assumed 2 visits in a year).
	<b>MOH</b>	0	0	<b>Current care:</b> No visits after year 1 <b>Target care:</b> No visits after year 1
<b>Investigation (MRI) (years 2-5)</b>	<b>Migraine</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
	<b>TTH</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
	<b>MOH</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
<b>Lost productivity</b>	We assumed that lost work productivity is correlated with disease-related disability, and reduced disability would bring reduced lost productivity. In our baseline scenario, all lost productivity was explained by disease-related disability.			
<b>Days lost from work in 12 months</b>	<b>Migraine</b>	7.6	3.9	<b>Current care:</b> based on Eurolight data [16] <b>Target care:</b> we assumed 49% decrease in lost productivity (equal to the gain in HLYs reported for migraine [see Table 4]): $7.6 - (7.6 * 0.49) = 3.9$ days.
	<b>TTH</b>	3.2	1.0	<b>Current care:</b> based on Eurolight data [16] <b>Target care:</b> we assumed 68% decrease in lost productivity (equal to the gain in HLYs reported for TTH [see Table 4]): $3.2 - (3.2 * 0.68) = 1.0$ days.
	<b>MOH</b>	22.8	11.6 (if revert to migraine); 7.3 (if revert to TTH)	<b>Current care:</b> based on Eurolight data [16] <b>Target care:</b> for individuals reverting to migraine, we assumed 49% decrease in lost productivity (equal to the gain in HLYs reported for migraine [see Table 4]): $22.8 - (22.8 * 0.49) = 11.6$ days for individuals reverting to TTH, we assumed 76% decrease in lost productivity (equal to the gain in HLYs reported for TTH [see Table 4]): $22.8 - (22.8 * 0.68) = 7.3$ days.

**Table 3: Treatment uptake, use of resources and lost productivity according to treatment management plan (Spain)**

	<b>Headache type</b>	<b>Current care (%)</b>	<b>Target care (%)</b>	<b>Notes</b>
<b>Uptake (including coverage and adherence)</b>	<b>Migraine</b>	88.6	94.3	<b>Current care:</b> 54.5% migraine non-specific + 20.4% migraine specific + 13.7% migraine prophylaxis = 88.6% (see treatment plan below) <b>Target care:</b> We assumed that structured services with consumer education and provider training enhances coverage and adherence so that uptake is increased by 50% of current deficit: medicines uptake = $[\{100\% - 88.6\}/2] + 88.6\%$ = 94.3%
	<b>TTH</b>	69.6	84.8	<b>Current care:</b> 69.6% acute medications; 0% TTH prophylaxis (see treatment plan below) <b>Target care:</b> We assumed as above: medicines uptake $[\{100\% - 69.6\}/2] + 69.6\%$ = 84.8%
	<b>MOH</b>	0	50.0	<b>Current care:</b> 0% treated <b>Target care:</b> We assumed that structured services with consumer education and provider training enhances treatment coverage and adherence so that proportion withdrawn from medicines overuse is increased by 50% of current deficit: withdrawal = $[\{100 - 0\}/2] + 0\%$ = 50.0%
<b>TREATMENT PLAN</b>				
<b>A. Acute management (non-specific drugs)</b>				
<b>Simple analgesics (eg, ASA 1 g)</b>	<b>Migraine</b>	54.5	47.2	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With provider training, treatment with simple analgesics alone is offered to 50% (expert assumption), with uptake = 47.2% (50% of 94.3%)
	<b>TTH</b>	69.6	82.3	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With provider training, treatment with simple analgesics alone is offered to 97% (expert assumption), with uptake = 82.3% (97% of 84.8%)
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>B. Acute management (specific drugs)</b>				
	<b>Migraine</b>	20.4	0	<b>Current care:</b> from Eurolight data [21]

<b>Sumatriptan 50 mg</b>				<b>Target care:</b> With provider training, treatment with specific drugs alone is offered to 0% (expert assumption)
	<b>TTH</b>	0	0	Not applicable to TTH care
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>C. Acute stepped care management</b>				
<b>ASA 1 g + sumatriptan 50 mg</b>	<b>Migraine</b>	0	18.9	<b>Current care:</b> not included in current care <b>Target care:</b> With provider training, acute stepped-care management is offered to 20% (expert assumption), with uptake = 18.9% (20% of 94.3%)
	<b>TTH</b>	0	0	Not applicable to TTH care
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>D. Prophylaxis + acute management</b>				
<b>Amitriptyline 100 mg/day + ASA 1 g + sumatriptan 50 mg</b>	<b>Migraine</b>	13.7	28.3	<b>Current care:</b> from Eurolight data [21] <b>Target care:</b> With provider training, prophylaxis + acute stepped-care management is offered to 30% (expert assumption), with uptake = 28.3% (30% of 94.3%)
	<b>TTH</b>	0	2.5	<b>Current care:</b> not included in current care <b>Target care:</b> With provider training, prophylaxis + acute care management is offered to 3% (expert assumption), with uptake = 2.5% (3% of 84.8%)
	<b>MOH</b>	0	0	Not applicable to MOH care
<b>Consultations and investigations</b>				
<b>Doctor visits (year 1)</b>	<b>Migraine</b>	25.1	50.0	<b>Current care:</b> 25.1% with migraine had seen a doctor (Eurolight data [21]), of whom 19.3% had seen a GP and 5.8% a specialist. We assumed 2 visits in either case. <b>Target care:</b> With consumer education, 50% see a doctor (expert assumption based on estimated need for professional care). Note that in the model those who see a specialist would see a GP first.
	<b>TTH</b>	9.4	2.25	<b>Current care:</b> 9.4% with TTH had seen a doctor (Eurolight data [21]), of whom 6.9% had seen a GP and 2.5% a specialist. We assumed 2 visits in either case.

				<p><b>Target care:</b> With consumer education, 3% (Stovner 2007 [38]) x 75% = 2.25% see a specialist and none see a GP (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2% with MOH had seen a doctor (Eurolight data [21]), of whom 21.6% had seen a GP and 29.6% a specialist. We assumed 2 visits in either case.</p> <p><b>Target care:</b> With consumer education, 100% see a doctor (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
<b>GP visits</b>	<b>Migraine</b>	19.3	45.0	<p><b>Current care:</b> 19.3% had seen a GP (Eurolight data [21])</p> <p><b>Target care:</b> With consumer education, 45.0% (90% of 50%) see a GP (we assumed 2 visits in a year)</p>
	<b>TTH</b>	6.9	0	<p><b>Current care:</b> 6.9% had seen a GP (2 times in a year) (Eurolight data [21])</p> <p><b>Target care:</b> Chronic TTH is difficult to treat, so we assumed that all should go to levels 2 or 3 (ie, "specialists").</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	21.6	100	<p><b>Current care:</b> 21.6% had seen a GP (2 times in a year) (Eurolight data [21])</p> <p><b>Target care:</b> With consumer education, 100% see a GP (we assumed 2 visits in a year)</p>
<b>Specialist visits</b>	<b>Migraine</b>	5.8	5.0	<p><b>Current care:</b> 5.8% had seen a specialist (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 5.0% (10% of 50%) see a specialist (we assumed 2 visits in a year)</p>
	<b>TTH</b>	2.5	2.25	<p><b>Current care:</b> 2.5% had seen a specialist (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 2.25% see a specialist (we assumed 2 visits in a year)</p>
	<b>MOH</b>	29.6	100	<p><b>Current care:</b> 29.6 % saw a GP (2 times in a year)</p> <p><b>Target care:</b> With consumer education and provider training, 100% see a specialist (we assumed 2 visits in a year)</p>
<b>Investigations (MRI) (year one)</b>	<b>Migraine</b>	8.5	1.0	<p><b>Current care:</b> All those seeing a specialist had MRI (one in a year)</p> <p><b>Target care:</b> With provider training, we assumed 1% have MRI (one in a year)</p>
	<b>TTH</b>	1.0	0.5	<p><b>Current care:</b> 1% had an MRI</p>



**Target care:** We assumed 0.5% have MRI examination (one in a year) – half the current estimate

	<b>MOH</b>	0	0	<p><b>Current care:</b> Nobody had an MRI</p> <p><b>Target care:</b> Nobody has an MRI</p>
<b>Doctor visits (years 2-5)</b>	<b>Migraine</b>	24.6	50.0	<p><b>Current care:</b> 24.6% with migraine had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 50% see a doctor (expert assumption based on estimated need for professional care)</p>
	<b>TTH</b>	9.4	2.25	<p><b>Current care:</b> 9.4% with TTH had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 3% (Stovner 2007 [38]) x 75% = 2.25% see a doctor (expert assumption based on estimated need for professional care).</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2% with MOH had seen a doctor (Eurolight data [21]), of whom all saw a GP only after year 1. We assumed 2 visits per year.</p> <p><b>Target care:</b> With consumer education, 100% see a doctor</p>
<b>GP visits</b>	<b>Migraine</b>	24.6	50.0	<p><b>Current care:</b> 24.6% saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> With consumer education, 50% see a GP. We assumed 2 visits each year.</p>
	<b>TTH</b>	9.4	0	<p><b>Current care:</b> 9.4% saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> Chronic TTH is difficult to treat, so we assumed that all should go to levels 2 or 3 (ie, "specialists").</p> <p>Note that those who see a specialist would see a GP first.</p>
	<b>MOH</b>	51.2	100	<p><b>Current care:</b> 51.2 % saw a GP. We assumed 2 visits each year.</p> <p><b>Target care:</b> With consumer education, 100% see a GP. We assumed 2 visits each year.</p>
<b>Specialist visits</b>	<b>Migraine</b>	0	0	<p><b>Current care:</b> No visits after year 1</p> <p><b>Target care:</b> No visits after year 1</p>
	<b>TTH</b>	0	2.25	<p><b>Current care:</b> No visits after year 1</p> <p><b>Target care:</b> With consumer education and provider training, 2.25% see a specialist (we assumed 2 visits in a year).</p>

	<b>MOH</b>	0	0	<b>Current care:</b> No visits after year 1 <b>Target care:</b> No visits after year 1
<b>Investigation (MRI) (years 2-5)</b>	<b>Migraine</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
	<b>TTH</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
	<b>MOH</b>	0	0	<b>Current care:</b> nobody had an MRI after year 1 <b>Target care:</b> nobody had an MRI after year 1
<b>Lost productivity</b>	We assumed that lost work productivity is correlated with disease-related disability, and reduced disability would bring reduced lost productivity. In our baseline scenario, all lost productivity was explained by disease-related disability.			
<b>Days lost from work in 12 months</b>	<b>Migraine</b>	7.6	2.4	<b>Current care:</b> based on Eurolight data [16] <b>Target care:</b> we assumed 69% decrease in lost productivity (equal to the gain in HLYs reported for migraine [see table 4]): $7.6 - (7.6 * 0.69) = 2.4$ days
	<b>TTH</b>	3.2	0.8	<b>Current care:</b> based on Eurolight data [16] <b>Target care:</b> we assumed 76% decrease in lost productivity (equal to the gain in HLYs reported for TTH [see table 4]): $3.2 - (3.2 * 0.76) = 0.8$ days
	<b>MOH</b>	22.8	7.1 (if revert to migraine); 5.5 (if revert to TTH)	<b>Current care:</b> based on Eurolight data [16] <b>Target care:</b> for individuals reverting to migraine, we assumed 69% decrease in lost productivity (equal to the gain in HLYs reported for migraine [see table 4]): $22.8 - (22.8 * 0.69) = 7.1$ days for individuals reverting to TTH, we assumed 76% decrease in lost productivity (equal to the gain in HLYs reported for TTH [see table 4]): $22.8 - (22.8 * 0.76) = 5.5$ days

**Table 4: Epidemiological data, disability weights, prevalence, frequency and duration of attacks**

		<b>Luxembourg</b>	<b>Russia</b>	<b>Spain</b>		
		<b>Value</b>	<b>Value</b>	<b>Value</b>	<b>Source</b>	<b>Specification</b>
<b>Population, overall</b>		586,869	143,500,000	46,064,604	[29]	2016 values
<b>Proportion 18-65 yrs old, %</b>		70	70.6	66	[30]	
<b>DW (% ictal disability)</b>	migraine	44.1	44.1	44.1	[26]	2015 values
	TTH	3.7	3.7	3.7	[26]	2015 values
	MOH	21.7	21.7	21.7	[26]	2015 values
<b>Prevalence %</b>	migraine	30.358	17.888	35.432	[1]	
	TTH	31.037	26.334	25.821	[1]	
	MOH	3.500	7.1	7.000	[1]	
<b>Mean frequency days/month</b>	migraine	4.4/30	4.4/30	4.4/30	[26]	
	TTH	3.5/30	3.5/30	3.5/30	[26]	
	MOH	23.1/30	23.1/30	23.1/30	[26]	
<b>Mean duration, hours (current)</b>	migraine	15	15	15	[26]	
	TTH	7.4	7.4	7.4	[26]	
<b>Mean duration, hours (target)</b>	migraine	2	2	2	expert opinion	
	TTH	2	2	2	expert opinion	
<b>YLDs (current)</b>	migraine	0.00040	0.00024	0.00047	[26]	
	TTH	0.00005	0.00003	0.00006	[26]	
	MOH	0.00020	0.00017	0.00017	[26]	

---

<b>YLDs (target)</b>	migraine	0.00005	0.00005	0.00005
	TTH	0.00585	0.01186	0.01170

---

DW: disability weight; TTH: tension type headache; MOH: medication-overuse headache; YLDs: years of healthy life lost to disability.  
YLDs = product of prevalence, mean frequency, mean duration and DW

**Table 5: Assumptions adopted when calculating the health effects**

<b>Efficacy</b>	
Efficacy of medications, migraine	ASA 1 g = 0.39 [28] Sumatriptan 50 mg = 0.35 [29] Amitriptyline 100 mg daily = 0.44 [30]
Efficacy of medications, TTH	ASA 1 g = 0.75 (expert opinion) Paracetamol 1 g = 0.59 [31] Amitriptyline 100 mg daily = 0.3 (expert opinion)
Efficacy of withdrawal, MOH	Efficacy = reverted to migraine 85%*2/3 + reverted to TTH 85%*1/3 + unchanged but off medications 15% (expert opinion)
<b>Uptake</b>	
Uptake of medications, migraine	ASA 1 g = 0.635 (expert opinion) Sumatriptan 50 mg = 0.005 (expert opinion) Amitriptyline 100 mg = 0.007 (expert opinion)
Uptake of medications, TTH	Analgesic ASA 1 g = 0.1 (expert opinion) Paracetamol 1 g = 0.456 (expert opinion) Amitriptyline 100 mg = 0 (expert opinion)
<b>Treatment efficacy (weighted by medications uptake)</b>	
Efficacy*uptake calculations	One medication = [proportion with effect] * [effect] * [uptake]; Combination of two medications = [(proportion with effect) <sub>medication A</sub> * (effect) <sub>medication A</sub> * (uptake) <sub>medication A</sub> ] + [(proportion with effect) <sub>medication B</sub> * (effect) <sub>medication B</sub> * (uptake) <sub>medication B</sub> ]
<b>Healthy life years (HLYs)</b>	
HLYs untreated = DW * proportion of time with headache (= number/year * duration in years);	
HLYs treated = HLYs untreated - HLY gained from treatment;	
HLYs gained = HLYs untreated * efficacy;	
Total HLYs gained per person = sum of (gains from each treatment * probability of having each treatment)	
HLYs gained across the population = HLY gained per person affected * prevalence.	
HLYs MOH treated = unchanged in 15% + migraine treated HLYs in 2/3*42.5% + TTH treated HLYs in 1/3*42.5%.	

**Table 6: Migraine costs (population estimates)**

	<b>Luxembourg</b> <b>N=124,713</b>		<b>Russia</b> <b>N=18,122,512</b>		<b>Spain</b> <b>N=10,772,263</b>	
	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>
<b>CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING</b>						
<b>Primary analysis</b>						
<b>Medications</b>						
acute non-specific ASA 1 g	7,568	35,364	855,296	3,996,867	508,399	2,375,791
acute-specific sumatriptan 50 mg	3,635	16,986	1,207,420	5,642,371	251,626	1,175,870
prophylaxis amitriptyline 100 mg/day	695	3,249	195,304	912,670	20,816	97,276
Total medications	11,898	55,599	2,258,020	10,551,908	780,841	3,648,937
<b>Health-care provision</b>						
GP visits	1,868,796	6,153,787	133,597,931	493,496,811	185,508,849	725,403,433
specialist visits	708,809	708,809	126,073,602	126,073,602	125,445,228	125,445,229
MRI	361,613	361,613	77,008,823	77,008,823	73,240,116	73,240,116
Total health-care provision	2,939,218	7,224,209	336,680,356	696,579,236	384,194,193	924,088,778
<b>Secondary analyses</b>						
Total lost productivity	120,885,706	564,908,477	2,045,525,786	9,558,904,021	4,136,426,354	19,329,847,995
Sensitivity analysis: disability accounts for 20% lost productivity	24,177,141	112,981,695	409,105,157	1,911,780,804	827,285,271	3,865,969,599
<b>TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING</b>						
<b>Primary analysis</b>						

<b>Medications</b>						
acute non-specific ASA 1 g	16,564	77,405	1,498,933	7,004,632	370,931	1,733,392
acute-specific sumatriptan 50 mg	153,854	718,974	50,269,478	234,913,251	10,313,113	48,193,995
prophylaxis amitriptyline 100 mg/day	30,050	140,425	7,857,564	36,719,020	899,802	4,204,845
Total medications	200,468	936,804	59,625,975	278,636,903	11,583,846	54,132,232
<b>Health-care provision</b>						
GP visits	4,357,297	12,893,134	373,410,366	1,104,912,154	399,420,967	1,181,876,886
specialist visits	611,042	611,042	74,160,942	74,160,942	46,119,569	46,119,569
MRI	62,347	62,347	9,059,861	9,059,861	5,385,303	5,385,303
Total health-care provision	5,030,686	13,566,523	456,631,169	1,188,132,957	450,925,839	1,233,381,758
<b>Secondary analyses</b>						
Total lost productivity	5,431,622	373,419,228	1,296,237,360	6,057,419,858	2,621,228,447	12,249,208,158
Sensitivity analysis: disability accounts for 20% lost productivity	1,086,324	74,683,846	259,247,472	1,211,483,972	524,245,689	2,449,841,632

**Table 7: TTH costs (population estimates)**

	<b>Luxembourg</b> <b>N=127,501</b>		<b>Russia</b> <b>N=26,679,239</b>		<b>Spain</b> <b>N=7,850,265</b>	
	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>
<b>CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING</b>						
<b>Primary analysis</b>						
<b>Medications</b>						
acute ASA 1 g or paracetamol 1 g	21,135	98,765	3,439,657	16,073,791	1,012,106	4,729,652.69
prophylaxis amitriptyline 100 mg/day	-	-	-	-	-	-
Total medications	21,135	98,765	3,439,657	16,073,791	1,012,106	4,729,652.69
<b>Health-care provision</b>						
GP visits	710,354	1,658,990	87,659,562	204,723,838	46,415,831	108,401,488
specialist visits	324,834	324,834	56,770,353	56,770,352	17,476,479	17,476,480
MRI	66,288	66,288	13,870,685	13,870,685	4,081,397	4,081,397
Health-care provision	1,101,476	2,050,112	158,300,600	275,364,875	67,973,707	129,959,365
<b>Secondary analyses</b>						
Total lost productivity	46,505,330	217,323,093	1,133,152,091	5,295,309,478	1,134,307,720	5,300,709,824
Sensitivity analysis: disability accounts for 20% lost productivity	9,301,066	43,464,618	226,630,418	1,059,061,896	226,861,544	1,060,141,965



	<b>Luxembourg</b> <b>N=127,501</b>		<b>Russia</b> <b>N=26,679,239</b>		<b>Spain</b> <b>N=7,850,265</b>	
<b>TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING</b>						
<b>Primary analysis</b>						
<b>Medications</b>						
acute ASA 1 g or paracetamol 1 g	31,184	145,724	4,063,501	18,989,061	497,776	2,326,148
prophylaxis amitriptyline 100 mg/day	3,122	14,590	1,175,568	5,493,524	66,639	311,410
Total medications	34,306	160,314	5,239,069	24,482,585	564,415	2,637,558
<b>Health-care provision</b>						
GP visits	222,734	222,734	13,742,996	13,742,996	14,553,862	14,553,862
specialist visits	281,115	281,115	49,129,551	49,129,551	15,124,295	15,124,295
MRI	31,870	31,870	6,668,783	6,668,783	1,962,264	1,962,264
Total health-care provision	535,719	535,719	69,541,330	69,541,330	31,640,421	31,640,421
<b>Secondary analyses</b>						
Total lost productivity	45,491,467	146,579,889	764,287,428	3,571,575,691	765,066,876	3,575,218,111
Sensitivity analysis: disability accounts for 20% lost productivity	20,397,967	29,315,978	152,857,486	714,315,138	153,013,375	715,043,622

**Table 8: MOH costs (population estimates)**

	<b>Luxembourg</b> <b>N=14,378</b>		<b>Russia</b> <b>N=7,193,081</b>		<b>Spain</b> <b>N=2,128,185</b>	
	<b>Cost (euros)</b> <b>1-year</b> <b>estimate</b>	<b>Cost (euros)</b> <b>5-year</b> <b>estimate</b>	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>	<b>Cost (euros)</b> <b>1-year estimate</b>	<b>Cost (euros)</b> <b>5-year estimate</b>
<b>CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING</b>						
<b>Primary analysis</b>						
<b>Total health-care costs</b>	571,570	2,670,992	168,632,151	788,031,399	89,782,290	419,559,753
<b>Secondary analyses</b>						
<b>Total lost productivity</b>	64,622,955	301,988,186	3,764,597,029	17,592,260,104	3,789,174,825	17,707,114,095
<b>Sensitivity analysis: disability accounts for 20% lost productivity</b>	12,924,591	60,397,637	752,919,406	3,518,452,021	757,834,965	541,422,818.96
<b>TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING</b>						
<b>Primary analysis</b>						
<b>Total health-care costs</b>	266,932	2,670,992	86,693,089	405,123,672	40,755,568	190,453,998
<b>Secondary analyses</b>						
<b>Total lost productivity</b>	9,011,897	42,113,311	520,108,800	2,430,509,620	523,504,417	2,446,377,605
<b>Sensitivity analysis: disability accounts for 20% lost productivity</b>	1,802,379	8,422,662	104,021,760	486,101,924	104,700,883	489,275,521

**Table 9: Healthy Life Years (HLYs) potentially gained in 1 year by each element of the proposed intervention (migraine)**

	Efficacy * uptake	Healthy Life Years per capita			Luxembourg N=124,713		Russia N=18,122,512		Spain N=10,772,263	
		Not treated	Treated	Gained	Affected individuals under treatment (n)	HLYs gained across population	Affected individuals under treatment (n)	HLYs gained across population	Affected individuals under treatment (n)	HLYs gained across population
<b>CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING</b>										
<b>A. Acute management (non-specific drugs) ASA 1 g</b>	0.2146	0.0399	0.0313	0.0086	79,193	0.0026	11,507,795	0.0015	6,840,387	0.0030
<b>B. Acute management (specific drugs) sumatriptan 50 mg</b>	0.0015	0.0399	0.0398	0.0001	624	1.83579E-05	90,613	1.08171E-05	53,861	0.0000
<b>C. Acute stepped-care management ASA 1 g + sumatriptan 50 mg</b>	0	0.0399	0.0399	0	0	0	0	0	0	0
<b>D. Prophylaxis + acute management amitriptyline 100 mg/day + ASA 1 g + sumatriptan 50 mg</b>	0.0031	0.0399	0.0397	0.0001	873	3.72807E-05	126,858	2.19671E-05	75,406	0.00004
<b>Total</b>					80,690	0.002656	11,725,266	0.001533	6,969,654	0.00304
<b>HLYs FOR OVERALL POPULATION</b>					<b>1,090</b>		<b>158,406</b>		<b>94,159</b>	
<b>TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING</b>										
<b>A. Acute management (non-specific drugs) ASA 1 g</b>	0.1386	0.0399	0.0343	0.0055	51,132	0.0017	7,430,230	0.0010	4,416,628	0.0020
<b>B. Acute management (specific drugs) sumatriptan 50 mg</b>	0	0.0399	0.0399	0	0	0		0		0

<b>C. Acute stepped-care management ASA 1 g + sumatriptan 50 mg</b>	0.1052	0.0399	0.0357	0.0042	153,854	0.0013	50,269,478	0.0008	10,313,113	0.0015
<b>D. Prophylaxis + acute management amitriptyline 100 mg/day + ASA 1 g + sumatriptan 50 mg</b>	0.2020	0.0399	0.0318	0.0081	30,679	0.0024	4,458,138	0.0014	2,649,977	0.0029
<b>Total</b>					235,666	0.0054	62,157,845	0.0032	17,379,718	0.0063
<b>HLYs FOR OVERALL POPULATION</b>					<b>2,217</b>		<b>322,115</b>		<b>191,470</b>	

**Table 10: Healthy Life Years (HLYs) potentially gained in 1 year by each element of the proposed intervention (TTH)**

	Efficacy * uptake	Healthy Life Years per capita			Luxembourg N=124,713		Russia N=18,122,512		Spain N=10,772,263	
		Not treated	Treated	Gained	Affected individuals under treatment (n)	HLYs gained across population	Affected individuals under treatment (n)	HLYs gained across population	Affected individuals under treatment (n)	HLYs gained across population
<b>CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING</b>										
Acute management ASA 1 g or paracetamol 1 g	0.3340	0.0013	0.0009	0.0004	70,890	0.0001	14,833,657	0.00012	4,364,748	0.00011
Prophylaxis + acute management amitriptyline 100 mg/day + ASA 1 g or paracetamol 1 g	0.3340	0.0013	0.0009	0.0004	0	0.0001	0	0.00012	0	0.00011
<b>Total</b>					70,890	0.0002	14,833,657	0.0026	4,364,748	0.00022
<b>HLYs FOR OVERALL POPULATION</b>					<b>112</b>		<b>23,398</b>		<b>6,885</b>	
<b>TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING</b>										
Acute management ASA 1 g or paracetamol 1 g	0.4847	0.0013	0.0007	0.0006	96,263	0.0002	2,0142,825	0.00017	5,926,950	0.00016
Prophylaxis + acute management amitriptyline 100 mg/day + ASA 1 g or paracetamol 1 g	0.4886	0.0013	0.0007	0.0006	3,188	0.0002	666,981	0.00017	196,257	0.00017
<b>Total</b>					99,451	0.0004	20,809,806	0.0026	6,123,207	0.00033
<b>HLYs FOR OVERALL POPULATION</b>					<b>163</b>		<b>34,090</b>		<b>10,031</b>	

**Table 11: Healthy Life Years (HLYs) potentially gained in 1 year by each element of the proposed intervention (MOH)**

	Healthy Life Years per capita			Luxembourg N=124,713		Russia N=18,122,512		Spain N=10,772,263	
	Not treated	Treated	Gained	Affected individuals under treatment (n)	HLYs gained across population	Affected individuals under treatment (n)	HLYs gained across population	Affected individuals under treatment (n)	HLYs gained across population
<b>CURRENT CARE: NO CONSUMER EDUCATION AND HEALTH CARE PROFESSIONAL TRAINING</b>									
No treatment coverage	0.1671	0	0	0	0	0	0	0	0
<b>HLYs FOR OVERALL POPULATION</b>					<b>0</b>		<b>0</b>		<b>0</b>
<b>TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH CARE PROFESSIONAL TRAINING</b>									
Treatment coverage	0.1671	0.2318	0.0647	6,110	0.0046	3,057,059	0.0046	904,478	0.0046
<b>HLYs FOR OVERALL POPULATION</b>					<b>776</b>		<b>388,112</b>		<b>114,829</b>

## Supplementary material

### Appendix 1: Unit costs

	<b>Luxembourg</b>	<b>Russia</b>	<b>Spain</b>	<b>References</b>
	<b>Cost per year per capita (euro) 2020</b>	<b>Cost per year per capita (euro) 2020</b>	<b>Cost per year per capita (euro) 2020</b>	
<b>MEDICINES</b>				[5,17,19]. Costs actualised to 2020 values using appropriate consumer price index [23]
<b>A. Acute management (non-specific drugs)</b>				
<b>ASA 1 g</b>	0.10	0.07	0.07	
<b>Paracetamol 1 g</b>	0.297	0.23	0.23	
<b>With consumer education</b>	0.33	0.21	0.08	
<b>B. Acute management (specific drugs)</b>				
<b>Sumatriptan 50 mg</b>	6.06	13.85	4.86	
<b>With consumer education and provider training</b>	6.07	14.09	4.87	
<b>C. Acute stepped-care management</b>				
<b>ASA 1 g + sumatriptan 50 mg</b>	6.16	17.35	4.94	
<b>With consumer education and provider training</b>	7.82	17.59	6.07	
<b>D. Prophylaxis + acute management</b>				
<b>Amitriptyline 100 mg + ASA 1 g + sumatriptan 50 mg</b>	0.83	1.60	0.29	
<b>With consumer education and provider training</b>	1.02	1.83	0.35	

---

**VISITS**

---

<b>One GP visit</b>	38.76	22.86	41.13	[20]
<b>One specialist visit</b>	48.92	40.85	42.74	[20]

---

**EXAMINATION**

---

<b>One MRI</b>	49.91	49.91	49.91	[7]
----------------	-------	-------	-------	-----

---

**PRODUCTIVITY**

---

<b>Daily wages</b>	205.01	23.87	81.21	[23]
--------------------	--------	-------	-------	------

---